BTI
CPRX

Blue Trust Inc’s Catalyst Pharmaceutical CPRX Stock Holding History

Blue Trust Inc’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-35
Closed -$542 – 2546
2024
Q3 		$542 Buy
+35
New +$649 ﹤0.01% 2787
2023
Q1 		– Sell
-35
Closed – – 2355
2022
Q4 		$0 Hold
35
– – ﹤0.01% 2268
2022
Q3 		$0 Hold
35
– – ﹤0.01% 2126
2022
Q2 		$0 Buy
+35
New +$257 ﹤0.01% 1906

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Blue Trust Inc's CPRX Position: Q4 2024 in Review

Blue Trust Inc sold out of Catalyst Pharmaceutical (CPRX) in Q4 2024, closing a stake of 35 shares — an estimated $542 sold.

Blue Trust Inc first reported a position in CPRX in Q2 2022 and held it in 4 quarters. The position peaked at $542 in Q3 2024. 336 funds tracked by Wall St. Rank hold CPRX as of Q4 2024.

  • Blue Trust Inc reported no remaining Catalyst Pharmaceutical position as of Q4 2024 after selling out during the quarter.
  • Blue Trust Inc sold 35 Catalyst Pharmaceutical shares in Q4 2024, an estimated $542.
  • Blue Trust Inc first reported a position in Catalyst Pharmaceutical in Q2 2022 and held it in 4 quarters.
  • Blue Trust Inc's Catalyst Pharmaceutical position peaked at $542 in Q3 2024.
  • 336 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q4 2024.

Based on Blue Trust Inc's 13F filing for Q4 2024, filed 22 Jan 2025.